Clinical Trial Update: A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) [Phase 1]

View source ↗

Summary

The Phase 1 trial evaluating EPI-7386 in combination with abiraterone acetate plus prednisone or with apalutamide in metastatic castration-resistant prostate ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Apalutamide (apalutamide)
• EPI-7386
• PREDNISONE (Prednisone)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Prostatic Neoplasms | Phase 1 | Status: TERMINATED